136 related articles for article (PubMed ID: 17018001)
1. Cysteine proteinase inhibitors as therapy for parasitic diseases: advances in inhibitor design.
Steverding D; Caffrey CR; Sajid M
Mini Rev Med Chem; 2006 Sep; 6(9):1025-32. PubMed ID: 17018001
[TBL] [Abstract][Full Text] [Related]
2. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design.
Lecaille F; Kaleta J; Brömme D
Chem Rev; 2002 Dec; 102(12):4459-88. PubMed ID: 12475197
[No Abstract] [Full Text] [Related]
3. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action.
McKerrow JH
Int J Parasitol; 1999 Jun; 29(6):833-7. PubMed ID: 10480720
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the synthesis, design and selection of cysteine protease inhibitors.
Hernandez AA; Roush WR
Curr Opin Chem Biol; 2002 Aug; 6(4):459-65. PubMed ID: 12133721
[TBL] [Abstract][Full Text] [Related]
5. Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy.
Caffrey CR; Scory S; Steverding D
Curr Drug Targets; 2000 Sep; 1(2):155-62. PubMed ID: 11465068
[TBL] [Abstract][Full Text] [Related]
6. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi.
Lalmanach G; Mayer R; Serveau C; Scharfstein J; Gauthier F
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):395-9. PubMed ID: 8809025
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents.
Yang PY; Wang M; Li L; Wu H; He CY; Yao SQ
Chemistry; 2012 May; 18(21):6528-41. PubMed ID: 22488888
[TBL] [Abstract][Full Text] [Related]
8. Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases.
Schad C; Baum U; Frank B; Dietzel U; Mattern F; Gomes C; Ponte-Sucre A; Moll H; Schurigt U; Schirmeister T
Antimicrob Agents Chemother; 2016 Feb; 60(2):797-805. PubMed ID: 26596939
[TBL] [Abstract][Full Text] [Related]
9. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
10. Targeting Cysteine Proteases from Plasmodium falciparum: A General Overview, Rational Drug Design and Computational Approaches for Drug Discovery.
Bekono BD; Ntie-Kang F; Owono Owono LC; Megnassan E
Curr Drug Targets; 2018; 19(5):501-526. PubMed ID: 28003005
[TBL] [Abstract][Full Text] [Related]
11. The anti-parasitic effects of nitric oxide.
Ascenzi P; Bocedi A; Gradoni L
IUBMB Life; 2003; 55(10-11):573-8. PubMed ID: 14711001
[TBL] [Abstract][Full Text] [Related]
12. Highly tunable thiosulfonates as a novel class of cysteine protease inhibitors with anti-parasitic activity against Schistosoma mansoni.
Ward DJ; Van de Langemheen H; Koehne E; Kreidenweiss A; Liskamp RMJ
Bioorg Med Chem; 2019 Jul; 27(13):2857-2870. PubMed ID: 31126821
[TBL] [Abstract][Full Text] [Related]
13. Optimization of peptidyl allyl sulfones as clan CA cysteine protease inhibitors.
Fennell BD; Warren JM; Chung KK; Main HL; Arend AB; Tochowicz A; Götz MG
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):468-78. PubMed ID: 22380780
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel class of falcipain-2 inhibitors as potential antimalarial agents.
Chakka SK; Kalamuddin M; Sundararaman S; Wei L; Mundra S; Mahesh R; Malhotra P; Mohmmed A; Kotra LP
Bioorg Med Chem; 2015 May; 23(9):2221-40. PubMed ID: 25840796
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of peptidyl-vinylaminophosphonates as novel cysteine protease inhibitors.
Bhattacharya AK; Rana KC
Bioorg Med Chem; 2011 Dec; 19(23):7129-35. PubMed ID: 22019466
[TBL] [Abstract][Full Text] [Related]
16. Cysteine protease inhibitors as chemotherapy for parasitic infections.
McKerrow JH; Engel JC; Caffrey CR
Bioorg Med Chem; 1999 Apr; 7(4):639-44. PubMed ID: 10353643
[TBL] [Abstract][Full Text] [Related]
17. Peptidyl beta-homo-aspartals (3-amino-4-carboxybutyraldehydes): new specific inhibitors of caspases.
Bajusz S; Fauszt I; Németh K; Barabás E; Juhász A; Patthy M; Bauer PI
Biopolymers; 1999; 51(1):109-18. PubMed ID: 10380358
[TBL] [Abstract][Full Text] [Related]
18. Use of inhibitors to identify essential cysteine proteinases of Trichomonas vaginalis.
Irvine JW; North MJ; Coombs GH
FEMS Microbiol Lett; 1997 Apr; 149(1):45-50. PubMed ID: 9103977
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of cysteine proteases.
Govardhan CP; Abeles RH
Arch Biochem Biophys; 1996 Jun; 330(1):110-4. PubMed ID: 8651683
[TBL] [Abstract][Full Text] [Related]
20. Effect of synthesized inhibitors on babesipain-1, a new cysteine protease from the bovine piroplasm Babesia bigemina.
Martins TM; Gonçalves LM; Capela R; Moreira R; do Rosário VE; Domingos A
Transbound Emerg Dis; 2010 Apr; 57(1-2):68-9. PubMed ID: 20537109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
